NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $71 | $88 | $214 | $335 |
| - Cash | $59 | $51 | $53 | $68 |
| + Debt | $0 | $1 | $3 | $4 |
| Enterprise Value | $12 | $38 | $163 | $271 |
| Revenue | $0 | $1 | $1 | $2 |
| % Growth | -71.6% | -59.1% | -36.7% | – |
| Gross Profit | -$0 | $0 | $0 | $1 |
| % Margin | -213.9% | 14.1% | 21.4% | 50.2% |
| EBITDA | -$25 | -$30 | -$40 | -$50 |
| % Margin | -14,912.1% | -5,239.9% | -2,812.1% | -2,233.8% |
| Net Income | -$28 | -$29 | -$38 | -$45 |
| % Margin | -16,769.7% | -4,947.9% | -2,688.8% | -2,007.1% |
| EPS Diluted | -0.33 | -0.35 | -0.46 | -0.55 |
| % Growth | 5.7% | 23.9% | 16.4% | – |
| Operating Cash Flow | -$23 | -$27 | -$40 | -$42 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$23 | -$27 | -$40 | -$42 |